Company: LIMN
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001410578-25-001746
Chunk: 199

Company: Liminatus Pharma, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 199
---
uant to applicable income tax treaties or other agreements, the IRS may make these reports available to tax authorities in your country of residence.

Payments of dividends on or of proceeds from the disposition of our Common Stock made to you may also be subject to backup withholding (currently at a rate of 24%) and additional information reporting unless you establish an exemption, for example, by certifying your non-U.S. status on a properly completed IRS Form W-8BEN or IRS Form W-8BEN-E or another appropriate version of IRS Form W-8. Notwithstanding the foregoing, backup withholding and information reporting may apply if either we or our paying agent has actual knowledge, or reason to know, that you are a U.S. person.

Backup withholding is not an additional tax; rather, the U.S. federal income tax liability of persons subject to backup withholding will be reduced by the amount of tax withheld. If withholding results in an overpayment of taxes, a refund or credit may generally be obtained from the IRS, provided that the required information is furnished to the IRS in a timely manner.

The preceding discussion of U.S. federal tax considerations is for general information only. It is not tax advice to investors in their particular circumstances. Each prospective investor should consult its own tax advisor regarding the particular U.S. federal, state and local, and non-U.S. tax considerations of purchasing, holding, and disposing of our Common Stock, including the consequences of any proposed change in applicable laws.

<div align='center'>126</div>

SELLING SECURITYHOLDERS The Selling Securityholders may offer and sell, from time to time, any or all of the shares of Common Stock being offered for resale by this prospectus, which consist of:

| ● | an aggregate of 10,169,406 shares of Common Stock issued as merger consideration shares in connection with the Liminatus Merger, which shares were issued at a deemed value of $10.00 per share pursuant to the terms of the Business Combination Agreement; |

| ● | an aggregate of 6,900,000 shares of Common Stock issued to the Sponsor upon conversion of founder shares prior to the IPO, which shares were purchased by the Sponsor at a price per share of $0.004; |

| ● | an aggregate of 1,500,000 shares of Common Stock issued to the PIPE Investor pursuant to the PIPE Equity Subscription Agreement; |

| ● | an aggregate of 835,555 shares of Common Stock issuable upon the exercise of 835,555 Private W